Peptomyc
Jörg Klumbis has a diverse work experience spanning over several companies. Jörg is currently serving as the CFO of Peptomyc, a company focused on developing cell penetrating peptides for cancer treatment. Prior to this, Jörg worked as a Co-founder and Partner at AIO Health Pro S.L., where they acted temporarily as CFO and provided services to the health sector. Jörg also worked as a Partner at WANRAX Consultant SL.
Jörg has extensive experience in the pharmaceutical industry, having served as the Executive Director of Finance and Administration at Invent Farma, a company that develops, manufactures, and markets generic drugs. Additionally, they worked as CFO at Laboratorios LETI, a multinational pharmaceutical group with expertise in immunotherapy vaccination and dermatology. Jörg also held various roles at Merck Group, including Head of Controlling and Project Controller.
Prior to their involvement in the pharmaceutical industry, Jörg worked at Uhde Edeleanu, where they served as Assistant Head of Project Controlling Department, Senior Project Controller, Business Controller, and Assistant to Management.
Overall, Jörg Klumbis has a strong background in finance and administration, with a specialization in the pharmaceutical industry.
Jörg Klumbis completed their high school education at Leibniz Gymnasium in Remscheid, where they earned their high school diploma. Following this, they attended Technische Universität Darmstadt from 1984 to 1991, where they specialized in electrical engineering and obtained a degree in Industrial Engineering. Later, in 1998 and 1999, Jörg attended IESE Business School to pursue a PDD (Program for Management Development) degree, although their field of study during this period is not specified.
This person is not in any teams
This person is not in any offices
Peptomyc
Peptomyc is a company focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.Currently,cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance.Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market.